Replimune Appoints New Commercial Chief; Neumora Shakes Up Executive Ranks
Replimune has hired Michelle DiNapoli, a former Genentech executive, as its chief commercial officer starting August 18, following the company's recent accelerated approval for a melanoma therapy. Separately, Neumora's CEO Paul Berns has stepped down from that role, with the company also naming a new chief medical officer. The leadership changes come as both firms navigate post-approval commercialization and pipeline development.
Related stories
Bicara Therapeutics appoints new CEO as current chief prepares to step down; former J&J executive joins Madrigal board · Drug development
Lonza adds commercial chief from Celonic; WuXi Biologics posts revenue gain · Drug development
STAT Investigation Examines Commure and Medicare's AI Device Incentives · Healthcare systems
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Replimune lands commercial chief after hard-fought approval; Neumora's Paul Berns sheds CEO title.” Browse more stories.